(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 May 2021 (20.05.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/094378 A9

(51) International Patent Classification:
*A61K 39/395* (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:
PCT/EP2020/081770

(22) International Filing Date:
11 November 2020 (11.11.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 62/933,672 | 11 November 2019 (11.11.2019) | US |
| 63/031,848 | 29 May 2020 (29.05.2020) | US |
| 63/089,345 | 08 October 2020 (08.10.2020) | US |


(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventors: **BERGLIND, Anna**; AstraZeneca AB SE-151 85, Södertälje (SE). **ABREU, Gabriel**; AstraZeneca AB SE-151 85, Södertälje (SE). **PINEDA, Lilia**; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, Delaware 19850 (US). **TUMMALA, Raj**; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, Delaware 19850 (US). **ASKANASE, Anca**; Department of Medicine,Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York (US). **RICHEZ, Christophe**; Rheumatology Department, CHU de Bordeaux-GH Pellegrin,, and UMR CNRS 5164, Bordeaux University, Bordeaux (FR). **MORAND, Eric**; Centre for Inflammatory Disease, Monash University, Clayton, VIC (AU). **BRUCE, Ian**; Centre for Epidemiology Versus Arthritis, Faculty of Biology, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester (GB). **BROHAWN, Philip**; AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **FURIE, Richard**; Division of Rheumatology, Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York (US). **BAE, Sang-Cheol**; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul (KR). **TANAKA, Yoshiya**; First Department of Internal Medicine and Graduate School of Medical Science, University of Occupational and Environmental Health, Kitakyushu (JP). **WERTH, Victoria**; University of Pennsylvania, Philadelphia, Pennsylvania (US). **VOLLENHOVEN, Ronald Van**; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam (NL). **ISENBERG, David**; Centre for Rheumatology, University College London, London (GB). **VITAL, Ed**; NIHR Leeds Biomedical Research Centre at Leeds Teaching Hospitals NHS Trust, Leeds (GB). **KAHLENBERG, Michelle**; Division of Rheumatology, University of Michigan, Ann Arbor, Michigan (US). **KALYANI, Rubana**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **KALUNIAN, Kenneth**; University of California, San Diego Health, La Jolla, California (US).

(74) Agent: **HUGHES, Rosemary**; AstraZeneca Intellectual Property Milstein Building, Granta Park, Cambridge Cambrigeshire CB21 6GH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
29 July 2021 (29.07.2021)

(15) Information about Correction:
see Notice of 29 July 2021 (29.07.2021)

(54) Title: TYPE I INTERFERON INHIBITION IN SYSTEMIC LUPUS ERYTHEMATOSUS

(57) Abstract: The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE). Specifically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.

WO 2021/094378 A9